Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond to these treatments, leaving them with drug-resistant tumors and few options. Now, scientists have found that two immune system molecules may be key to the development of drug resistance in estrogen-driven breast cancers.